Black Diamond Therapeutics, Inc. 8K

Black Diamond Therapeutics announced Q2 2026 results and clinical progress for silevertinib, with strong Phase 2 data in NSCLC, ongoing GBM studies, and sufficient cash to fund operations into 2H 2028.

Black Diamond Therapeutics, Inc. reported its second quarter 2026 financial results and provided a corporate update, highlighting positive Phase 2 data for its investigational EGFR inhibitor silevertinib in frontline non-classical EGFR-mutant NSCLC presented at the 2026 ASCO Annual Meeting, continued enrollment of a Phase 2 trial in EGFRvIII+ glioblastoma, and plans to seek FDA feedback on a pivotal development path for silevertinib with an update expected in Q4 2026, while disclosing a quarter-end cash, cash equivalents, and investments balance of $110.5 million (projected to fund operations into the second half of 2028) and a quarterly net loss of $9.9 million.

Filing Facts

CIK

1701541

Ticker

-

Form

8K

Source Type

sec

Accession

0001701541-26-000023

Alert Tier

6